Results 111 to 120 of about 2,901,175 (369)

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Hybridizing PSM and RSM Operator for Solving NP-Complete Problems: Application to Travelling Salesman Problem [PDF]

IJCSI International Journal of Computer Science Issues, Vol. 9, Issue 1, No 1, 2012, 374-378, 2012
In this paper, we present a new mutation operator, Hybrid Mutation (HPRM), for a genetic algorithm that generates high quality solutions to the Traveling Salesman Problem (TSP). The Hybrid Mutation operator constructs an offspring from a pair of parents by hybridizing two mutation operators, PSM and RSM.
arxiv  

The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine

Human Genetics, 2013
The Human Gene Mutation Database (HGMD®) is a comprehensive collection of germline mutations in nuclear genes that underlie, or are associated with, human inherited disease.
P. Stenson, M. Mort, E. Ball, Katy Shaw, A. Phillips, D. Cooper   +5 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Patterns of mutations in TP53 mutated AML [PDF]

Best Practice & Research Clinical Haematology, 2018
TP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy.
openaire   +3 more sources

Towards Advanced Phenotypic Mutations in Cartesian Genetic Programming [PDF]

arXiv, 2018
Cartesian Genetic Programming is often used with a point mutation as the sole genetic operator. In this paper, we propose two phenotypic mutation techniques and take a step towards advanced phenotypic mutations in Cartesian Genetic Programming. The functionality of the proposed mutations is inspired by biological evolution which mutates DNA sequences ...
arxiv  

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Proceedings of the National Academy of Sciences of the United States of America, 2008
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug ...
C. Yun, Kristen E. Mengwasser, A. Toms, M. S. Woo, H. Greulich, Kwok-kin Wong, M. Meyerson, M. Eck   +7 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Mutating Brauer trees [PDF]

arXiv, 2010
In this paper we introduce mutation of Brauer trees. We show that our mutation of Brauer trees explicitly describes the tilting mutation of Brauer tree algebras introduced by Okuyama and Rickard.
arxiv  

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source